Who is sponsoring NCT04475159?

NCT04475159 is sponsored by Prof. Aviram Nissan.

What drugs are being tested in NCT04475159?

Interventions in NCT04475159: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC).

What condition does NCT04475159 study?

NCT04475159 studies Metastatic Colorectal Cancer, Peritoneal Carcinomatosis, Colon Adenocarcinoma.

Is NCT04475159 still recruiting?

NCT04475159 is currently status unknown. Last updated 17 July 2020.

Last reviewed 2020-07-17 · How we verify

NCT04475159

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combined Neoadjuvant Systemic and PIPAC Therapy (NASPIT) for Patients With Colorectal Peritoneal Metastasis Eligible for CRS and HIPEC: A Prospective Phase II Trial

Status unknown Phase 2 Last updated 17 July 2020

What this trial tests

Phase 2 trial testing Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Metastatic Colorectal Cancer in 50 participants. Status unknown.

Timeline

1 August 2020

Primary endpoint
1 August 2022

1 August 2023

Quick facts

Lead sponsor	Prof. Aviram Nissan
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	1 August 2020
Primary completion	1 August 2022
Estimated completion	1 August 2023

Drugs / interventions tested

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) — full drug profile →

Conditions studied

Metastatic Colorectal Cancer — all drugs for Metastatic Colorectal Cancer →
Peritoneal Carcinomatosis — all drugs for Peritoneal Carcinomatosis →
Colon Adenocarcinoma — all drugs for Colon Adenocarcinoma →

Sponsor

Prof. Aviram Nissan

Who can join

18 and older, any sex, with Metastatic Colorectal Cancer or Peritoneal Carcinomatosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel drug-delivery system developed to deliver, effectively and safely, small doses of cytotoxic agents into peritoneal tumor deposits. It is currently used for palliation and for down-staging of patients who are non-eligible for cytoreductive surgery (CRS) and hyperthermic intra-peritoneal chemotherapy (HIPEC). The aim of this study is to evaluate the efficacy of PIPAC used in neoadjuvant setting to enhance the response of patients with colorectal peritoneal metastasis when combined with neoadjuvant systemic therapy for patients eligible to CRS/HIPEC prior to planned surgery.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

PIPAC for Gastrointestinal Malignancies.
Daniel SK, Sun BJ, Lee B. · · 2023 · cited 15× · PMID 37959264 · DOI 10.3390/jcm12216799
Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies.
Harper MM, Kim J, Pandalai PK. · · 2022 · cited 14× · PMID 35628966 · DOI 10.3390/jcm11102840
Is PIPAC a Treatment Option in Upper and Lower Gastrointestinal Cancer with Peritoneal Metastasis?
Guel-Klein S, Alberto Vilchez ME, Ceelen W, Rau B, et al · · 2022 · cited 3× · PMID 35614892 · DOI 10.1159/000523901
Physiological Considerations and Delivery Strategies for Targeting Tumors Through Intraperitoneal Delivery.
Jony MJH, Ranjbar S, Prajapati R, Eslami SM, et al · · 2025 · cited 2× · PMID 40855029 · DOI 10.1007/s11095-025-03917-0

Verify or expand the search:

Other recruiting trials for Metastatic Colorectal Cancer

Currently open trials in the same condition.

NCT07416552 — A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC) · Phase 1 · recruiting
NCT07314294 — Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients · Phase 2 · recruiting
NCT06856837 — - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Misma · Phase 2 · recruiting
NCT06959550 — Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorect · Phase 2 · recruiting
NCT06808685 — Real World Multicenter National Study to Evaluate the Effectiveness and Safety of Biosimilar Bevacizumab Elovie · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04475159 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Prof. Aviram Nissan
Last refreshed: 17 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04475159.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing